Stay updated on Durvalumab & Tremelimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.

Latest updates to the Durvalumab & Tremelimumab in NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.6.3 is now shown on the page, replacing v3.6.2, indicating an internal version update to the page metadata.SummaryDifference0.0%

- Check18 days agoChange DetectedThe revision label on the page updated from v3.6.0 to v3.6.2, indicating a newer page version has been published.SummaryDifference0.0%

- Check33 days agoChange DetectedAdds recruitment-status notice and new user guidance sections, and updates the Intervention/Treatment label and revision version, while removing the older revision label.SummaryDifference0.1%

- Check40 days agoChange DetectedThe page now shows Revision: v3.5.5, replacing Revision: v3.5.4. This indicates a minor update to the page template.SummaryDifference0.0%

- Check61 days agoChange DetectedThe page revision label was updated from v3.5.3 to v3.5.4, and the old AstraZeneca study locator contact block was removed.SummaryDifference0.0%

- Check83 days agoChange DetectedThe page’s footer has updated the ClinicalTrials.gov interface revision/version from v3.5.2 to v3.5.3. This reflects a platform update rather than a change to the displayed study details.SummaryDifference0.0%

Stay in the know with updates to Durvalumab & Tremelimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.